Dulaglutide Injection Shortage

• • Lilly has Trulicity available.

• • Trulicity subcutaneous solution for injection, Lilly USA, LLC, 0.75 mg/0.5 mL, pen injector, 4 count, NDC 00002-1433-80
  • Trulicity subcutaneous solution for injection, Lilly USA, LLC, 1.5 mg/0.5 mL, pen injector, 4 count, NDC 00002-1434-80
  • Trulicity subcutaneous solution for injection, Lilly USA, LLC, 3 mg/0.5 mL, pen injector, 4 count, NDC 00002-2236-80
  • Trulicity subcutaneous solution for injection, Lilly USA, LLC, 4.5 mg/0.5 mL, pen injector, 4 count, NDC 00002-3182-80

Implications for Patient Care

• • Dulaglutide is a GLP-1 receptor agonist that increases post-prandial insulin secretion, reduces glucagon secretion, and slows gastric emptying.[1]
  • Dulaglutide is combined with diet and exercise to improve glycemic control in patients aged 10 and older with type 2 diabetes mellitus.[1]

Safety

• • Lily warned that counterfeiters and compounding pharmacies are dispensing products that are not FDA-approved. The FDA or any global regulatory agency has not reviewed these products for safety, quality, or efficacy. These products may expose patients to serious risks. Lily encourages patients and providers to report suspected counterfeit products to the Lilly Answers Center (TLAC) at 1-800-LillyRx (1-800-545-5979).[2]

Alternative Agents & Management

• • The American Diabetes Association (ADA) describes GLP-1 therapy in adults with type 2 diabetes in section 9 of the standards of care in diabetes.[3]
  • The ADA lists tirzepatide, semaglutide, and high-dose dulaglutide as very effective GLP agents in glucose-lowering.[3]
  • The ADA lists semaglutide and tirzepatide as very effective GLP agents for weight loss in patients with type 2 diabetes.[3]
  • Alternative agents that can have moderate effects on glucose-lowering and aid in weight loss are dulaglutide and liraglutide.[3]

References

• 1. Trulicity (dulaglutide) injection, solution. Package insert. Lilly; 2024. Accessed August 8, 2024. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=463050bd-2b1c-40f5-b3c3-0a04bb433309#section-11.1
  2. Lilly Medicine Supply Information | Lilly Supply Info. Accessed August 9, 2024. https://supply.lilly.com/supply.lilly.com
  3. American Diabetes Association Professional Practice Committee. 9. Pharmacologic Approaches to Glycemic Treatment: Standards of Care in Diabetes2024. Diabetes Care. 2023;47(Supplement_1):S158-S178. doi:10.2337/dc24-S009